THRA
MOLECULAR TARGETthyroid hormone receptor alpha
THRA (thyroid hormone receptor alpha) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting THRA
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | amiodarone | 4.51 | 90 |
| 2 | liothyronine | 4.23 | 68 |
| 3 | Triiodothyronine | 3.56 | 34 |
| 4 | roxadustat | 3.18 | 23 |
| 5 | tiratricol | 3.04 | 20 |
| 6 | sobetirome | 2.40 | 10 |
| 7 | tetrac | 2.08 | 7 |
| 8 | thyropropic acid | 1.79 | 5 |
| 9 | eprotirome | 1.79 | 5 |
| 10 | resmetirom | 1.79 | 5 |
| 11 | Thyroxine | 1.10 | 2 |
| 12 | Thyroxine | 1.10 | 2 |
| 13 | Dextrothyroxine | 0.69 | 1 |
About THRA as a Drug Target
THRA (thyroid hormone receptor alpha) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented THRA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
THRA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.